Home>Topics>Stocks>MAP Pharmaceuticals

MAP Pharmaceuticals MAPP

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Pepco Holdings Inc

      Stock Reports

      Thu, 10 Jul 2014

      address regulatory lag.The cancelation of the $1.2 billion MAPP transmission project, which would have provided a generous 12 ..... Atlantic Power Pathway project, citing low demand. Absent MAPP , reliability-driven distribution and transmission spending

    2. Allergan Will Control Migraine Portfolio Through Planned MAP Acquisition

      Commentary

      Wed, 23 Jan 2013

      Allergan AGN announced it intends to acquire MAP Pharmaceuticals for approximately $950 million. The news is not particularly surprising because both companies formed a partnership in 2011 for

    3. MAP Pharma shares dive after FDA rejects migraine treatment

      Headlines

      Tue, 27 Mar 2012

      (Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...

    4. Dropping Coverage of MAP Pharmaceuticals

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on MAP Pharmaceuticals MAPP . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    5. MAPP Transmission Project Delay In Line With Our Expectations for Pepco

      Commentary

      Fri, 19 Aug 2011

      the projected in-service date for the MAPP transmission project by four to six years ..... be the best-case scenario. Given that MAPP promises 12.8% federally approved returns ..... violations earlier than 2019, making the MAPP transmission project unnecessary at this

    6. New Credit Rating: Pepco Holdings Inc.

      Commentary

      Tue, 16 Aug 2011

      insensitive to decreased customer usage from unfavorable weather, a poor economy, or energy efficiency improvements. If the high-returning MAPP transmission project ever gets off the ground, then overall returns should improve moderately.

    7. No Surprises in Second Quarter Results for Pepco Holdings; Reaffirming Fair Value Estimate

      Commentary

      Fri, 5 Aug 2011

      Supply business. Weather had a negligible impact on results, since 64% of distribution revenue is decoupled from usage. Later this month, we expect PJM to push out the timing of its lucrative MAPP transmission project by at least six months.

    8. New Morningstar Analyst Report - MAP Pharmaceuticals , Inc.

      Stock Reports

      Wed, 8 Jun 2011

      more than two years, and we give it fair marks overall. MAP Pharmaceuticals reformulates existing drugs in an attempt to offer safer ..... will not generate any significant revenue until then. MAP Pharmaceuticals followed a setback in its drug portfolio with a huge success

    9. Allergan Wraps Up 2010 With Strong 4Q

      Commentary

      Wed, 2 Feb 2011

      procedure will result in gradual adoption over time. Allergan's recent joint-venture announcement with MAP Pharmaceuticals MAPP to market Levadex now makes Allergan one of the few firms marketing branded products to headache specialists

    10. MAP Announces Partnership With Allergan for Lead Drug Levadex

      Commentary

      Mon, 31 Jan 2011

      MAP Pharmaceuticals MAPP announced Monday it will partner with Allergan AGN to copromote MAP's lead drug candidate Levadex, its inhaled therapy for migraine

    « Prev12Next »
    Content Partners